In the autumn of 1991, doctors at 20 clinics across Italy began handing 262 adults a six-month supply of tablets, half of them containing 600 milligrams of N-acetylcysteine and half containing nothing at all. Most of the volunteers were 65 or older, many were living with a chronic illness that had nothing to do with their lungs, and none had received a flu shot that season or the one before it.
By the following spring, the flu had moved through the group without regard to which bottle anyone was taking. What differed was what happened after the virus arrived, and that distinction is the one worth carrying into a pharmacy aisle this November, when NAC for cold and flu season starts appearing on shelf talkers and wellness feeds again.
The short answer is that the human evidence for NAC during respiratory season is real but narrow. One older trial in mostly elderly adults found fewer and milder flu-like illnesses without any drop in infection, and the larger lung trials split on whether NAC prevents flare-ups in people who already have chronic obstructive pulmonary disease.
The Italian Trial That Still Anchors the Claim
The study, led by Silvio De Flora of the University of Genoa with colleagues from Pavia and the drug maker Zambon, was published in the European Respiratory Journal in 1997. Participants took one 600 milligram tablet twice a day from October or November 1991 through April or May 1992, a window the authors chose to cover the cold season, and the virus peaked between December and March.
Among people taking placebo, 51 percent reported at least one influenza-like episode. In the NAC group the figure was 29 percent, a difference the authors reported as statistically significant. The illnesses that did occur under NAC also skewed lighter, with 72 percent rated mild and 2 percent severe, against 48 percent mild and 6 percent severe in the placebo group, and time spent in bed was lower in the treated group at several monthly checkpoints.
The researchers tested antibodies against the A/H1N1 strain circulating that winter and found that 24 percent of the placebo group and 29 percent of the NAC group had been infected, figures that sit close enough to mean the supplement did nothing to keep the virus out. What changed was the experience of the infection itself: only 25 percent of infected people taking NAC developed symptoms, compared with 79 percent of infected people on placebo.
That is the most useful sentence in the paper and also the most misread one. The trial points toward milder influenza-like illness in older adults rather than protection from catching anything, and the authors themselves framed NAC as something that left the infection in place while blunting its symptoms. Read the original 1997 paper and the limits are visible on the page: one viral strain measured, symptoms collected by checklist, 19 percent of the placebo group and 14 percent of the NAC group lost to follow-up, and tablets supplied by the company that made the drug.
What Happened When Researchers Tested NAC in Damaged Lungs
The Italian investigators deliberately excluded anyone with chronic lung disease, which left the most obvious population for a mucus-thinning compound to other trials. Two of them, published nine years apart, landed in different places.
The first, called BRONCUS, enrolled 523 people with COPD at 50 centres and gave them 600 milligrams of NAC once a day or a placebo for three years. Published in The Lancet in 2005, it found that lung function declined at essentially the same pace in both groups, 54 milliliters a year on NAC against 47 on placebo, and that exacerbations arrived at nearly identical rates of 1.25 and 1.29 per patient per year. The authors concluded that NAC at that dose did not slow the disease or prevent its flare-ups, while noting a possible benefit in the subgroup of patients who were not using inhaled corticosteroids.
The second, PANTHEON, doubled the dose. Investigators at 34 academic pulmonary clinics in China randomized 1,006 patients between 40 and 80 years old with moderate to very severe COPD to 600 milligrams twice a day or placebo for a year. The results, published in The Lancet Respiratory Medicine in 2014, showed a 22 percent lower annual rate of exacerbations in the NAC group, a risk ratio of 0.78 with a confidence interval running from 0.67 to 0.90.
Jinping Zheng of the Guangzhou Institute of Respiratory Disease, speaking for the research team in an interview with MedicalResearch.com that February, said oral NAC "is recommended as a valuable treatment for prevention of progression in patients with COPD" and suggested it works best at higher doses, taken for longer, and started at moderate severity. Pulmonologists reviewing the paper raised the caveats that travel with it: the patients were all treated in China, exacerbations were counted largely from self-reported diaries, and the trial did not show fewer hospitalizations.
Dose is the variable that keeps reappearing
Set side by side, the two COPD trials differ most in the amount of NAC each patient swallowed. BRONCUS used 600 milligrams a day and found nothing; PANTHEON used 1,200 milligrams a day and found a modest reduction. The Italian flu trial also used 1,200 milligrams a day, split into two doses. No head-to-head trial has settled the question, and populations, eras and outcome definitions all differ between the three, so the pattern is a lead rather than a rule.
It does explain why many supplement bottles sit at 600 milligrams per capsule with directions that vary from one a day to two. Anyone comparing products this winter should know that the positive human data on respiratory outcomes come from twice-daily schedules taken for six months to a year, not from a few capsules swallowed at the first scratch in the throat.
Where the Biology Fits and Where It Stops
NAC has two well-established medical jobs, which our plain-language guide to what NAC does walks through in detail. Hospitals use it as the antidote to acetaminophen overdose because it restores the liver's supply of glutathione, and clinicians have long used it to loosen thick mucus in chronic bronchitis and cystic fibrosis by breaking the chemical bonds that hold mucus proteins together.
Both mechanisms make a respiratory benefit plausible. Glutathione is one of the body's principal antioxidant defenses in the lining of the airways, and NAC supplies cysteine, the building block the body uses to make more of it. That raises a fair question about whether taking glutathione directly would do the same job, which the trials we reviewed in our comparison of oral glutathione and NAC answer with far more caution than the marketing does.
Plausibility, however, is where the evidence for the most popular uses ends. No large modern trial has tested NAC against the respiratory viruses now circulating in a general adult population, and the 1997 study predates current flu vaccines, current antivirals and current definitions of what counts as a clinically meaningful episode. The authors excluded vaccinated volunteers, so their findings say nothing about whether NAC adds anything on top of a flu shot.
Reading the Evidence Before You Buy
For a healthy adult hoping to avoid catching a cold, the human data offer no support for NAC as prevention, since the only trial to measure infection directly found it unchanged. For an older adult interested in softening a bad flu season, there is one industry-supported trial from the early 1990s showing fewer symptomatic illnesses, a result that has never been reproduced at that scale.
For someone living with COPD, the picture is more developed and also more medical. A once-daily dose failed in BRONCUS and a twice-daily dose helped in PANTHEON, and the question of whether to add NAC belongs in a conversation with the pulmonologist who already manages that patient's inhalers. NAC can interact with some prescription drugs, and people with asthma or a history of stomach ulcers have particular reasons to check first.
Quality matters as much as dose. NAC has occupied an unsettled regulatory position in the United States since the Food and Drug Administration's warning letters of 2020 and 2021, which means the bottle on the shelf answers to supplement rules rather than drug manufacturing standards. A product carrying third-party verification of identity and strength offers the strongest assurance that the milligrams on the label match what the trials used.
The most honest summary of the research may be the one the Italian data already contain. Twenty-nine percent of the NAC group became infected with the flu, roughly the same share as the placebo group, and three quarters of those infected people never felt sick enough to report it.